Genovis AB (publ.)

OM:GENO Stock Report

Market Cap: SEK 1.8b

Genovis AB (publ.) Valuation

Is GENO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GENO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GENO (SEK28.05) is trading above our estimate of fair value (SEK22.26)

Significantly Below Fair Value: GENO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GENO?

Key metric: As GENO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GENO. This is calculated by dividing GENO's market cap by their current earnings.
What is GENO's PE Ratio?
PE Ratio65.8x
EarningsSEK 27.91m
Market CapSEK 1.80b

Price to Earnings Ratio vs Peers

How does GENO's PE Ratio compare to its peers?

The above table shows the PE ratio for GENO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63x
MAGLE Magle Chemoswed Holding
36.9xn/aSEK 622.0m
MCAP MedCap
33.3xn/aSEK 7.8b
BIOT Biotage
46.6x19.5%SEK 12.1b
ALIF B AddLife
135.3x52.0%SEK 16.1b
GENO Genovis AB (publ.)
65.8x16.4%SEK 1.8b

Price-To-Earnings vs Peers: GENO is expensive based on its Price-To-Earnings Ratio (65.8x) compared to the peer average (63x).

Price to Earnings Ratio vs Industry

How does GENO's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
GENO 65.8xIndustry Avg. 37.1xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GENO is expensive based on its Price-To-Earnings Ratio (65.8x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is GENO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GENO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio65.8x
Fair PE Ratio34.1x

Price-To-Earnings vs Fair Ratio: GENO is expensive based on its Price-To-Earnings Ratio (65.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GENO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 28.05
SEK 39.00
+39.0%
25.7%SEK 53.00SEK 30.00n/a3
Nov ’25SEK 21.75
SEK 38.00
+74.7%
26.8%SEK 52.00SEK 28.00n/a3
Oct ’25SEK 26.05
SEK 43.00
+65.1%
20.9%SEK 52.00SEK 34.00n/a2
Sep ’25SEK 25.30
SEK 43.00
+70.0%
20.9%SEK 52.00SEK 34.00n/a2
Aug ’25SEK 29.00
SEK 51.50
+77.6%
26.2%SEK 65.00SEK 38.00n/a2
Jul ’25SEK 27.70
SEK 51.50
+85.9%
26.2%SEK 65.00SEK 38.00n/a2
Jun ’25SEK 38.25
SEK 51.50
+34.6%
26.2%SEK 65.00SEK 38.00n/a2
May ’25SEK 27.85
SEK 50.50
+81.3%
24.8%SEK 63.00SEK 38.00n/a2
Apr ’25SEK 33.40
SEK 55.50
+66.2%
13.5%SEK 63.00SEK 48.00n/a2
Mar ’25SEK 38.35
SEK 68.00
+77.3%
10.3%SEK 75.00SEK 61.00n/a2
Feb ’25SEK 52.40
SEK 75.67
+44.4%
9.0%SEK 81.00SEK 66.00n/a3
Jan ’25SEK 52.00
SEK 75.67
+45.5%
9.0%SEK 81.00SEK 66.00n/a3
Dec ’24SEK 49.70
SEK 75.67
+52.2%
9.0%SEK 81.00SEK 66.00n/a3
Nov ’24SEK 43.90
SEK 80.33
+83.0%
14.7%SEK 95.00SEK 66.00SEK 21.753
Oct ’24SEK 46.40
SEK 80.33
+73.1%
14.7%SEK 95.00SEK 66.00SEK 26.053
Sep ’24SEK 52.70
SEK 87.50
+66.0%
8.6%SEK 95.00SEK 80.00SEK 25.302
Aug ’24SEK 47.75
SEK 85.50
+79.1%
6.4%SEK 91.00SEK 80.00SEK 29.002
Jul ’24SEK 47.15
SEK 85.50
+81.3%
6.4%SEK 91.00SEK 80.00SEK 27.702
Jun ’24SEK 52.60
SEK 85.50
+62.5%
6.4%SEK 91.00SEK 80.00SEK 38.252
May ’24SEK 59.10
SEK 82.00
+38.7%
8.5%SEK 89.00SEK 75.00SEK 27.852
Apr ’24SEK 66.30
SEK 82.00
+23.7%
8.5%SEK 89.00SEK 75.00SEK 33.402
Mar ’24SEK 57.20
SEK 82.00
+43.4%
8.5%SEK 89.00SEK 75.00SEK 38.352
Feb ’24SEK 62.00
SEK 76.00
+22.6%
7.9%SEK 82.00SEK 70.00SEK 52.402
Jan ’24SEK 45.95
SEK 71.00
+54.5%
15.5%SEK 82.00SEK 60.00SEK 52.002
Nov ’23SEK 39.05
SEK 70.00
+79.3%
14.3%SEK 80.00SEK 60.00SEK 43.902

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

AstraZeneca

UK£154.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,392.50

7D

-1.0%

1Y

4.7%

Swedish Orphan Biovitrum

SEK 102.4b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 298.20

7D

-9.1%

1Y

23.3%

Ascelia Pharma

SEK 252.2m

A biotech company, focuses on orphan oncology treatments in Sweden.

ACE

SEK 2.63

7D

-0.9%

1Y

-9.3%